Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Radezolid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.56 |
| ▸ | CALML3 | P27482 | 7/20 | 0.51 |
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | SDHA | P31040 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Radezolid SCHEMBL3165892 | 1.00 | MAOA (0.56) | MAOACALML3MAOBLMNAPTGS1 | |
| Radezolid SCHEMBL30061945 | 1.00 | MAOA (0.56) | MAOACALML3MAOBLMNAPTGS1 | |
| Radezolid SCHEMBL15633880 | 0.99 | MAOA (0.55) | MAOACALML3MAOBLMNAPTGS1 | |
| Radezolid SCHEMBL2723587 | 0.99 | MAOA (0.55) | MAOACALML3MAOBLMNAPTGS1 | |
| Radezolid SCHEMBL15634976 | 0.97 | MAOA (0.53) | MAOACALML3MAOBLMNAPTGS1 | |
| Radezolid SCHEMBL15634852 | 0.97 | MAOA (0.53) | MAOACALML3MAOBLMNAPTGS1 | |
| Radezolid SCHEMBL15634749 | 0.96 | MAOA (0.52) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL12956217 | 0.93 | MAOA (0.54) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL1032249 | 0.93 | MAOA (0.54) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL1036539 | 0.93 | MAOA (0.54) | MAOACALML3MAOBLMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727950-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2026-04-22 | — | — | EP | claimed |
| US-20260048047-A1 | SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE | SCRIPPS RESEARCH INST (US) | 2026-02-19 | — | — | US | claimed |
| US-20260027140-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | ATOPIC MEDICAL INC (US) | 2026-01-29 | — | — | US | claimed |
| EP-4027535-B1 | WIRELESS TRANSCEIVER DEVICE INTEGRATED WITH COMMON CLOCK PHASE-LOCKED LOOP | HUAWEI TECH CO LTD (CN) | 2025-12-03 | — | — | EP | claimed |
| US-12465623-B2 | Use of parasites and extracellular vesicles obtained from parasites in cancer treatment | YEDITEPE UNIVERSITESI (TR) | 2025-11-11 | — | — | US | claimed |
| EP-3965808-B1 | USE OF PARASITES AND EXTRACELLULAR VESICLES OBTAINED FROM PARASITES IN CANCER TREATMENT | UNIV YEDITEPE (TR) | 2025-09-03 | — | — | EP | claimed |
| WO-2025096495-A1 | ARYL FLUOROSULFATE-BASED INHIBITORS AS NOVEL ANTITUBERCULAR AGENTS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2025-05-08 | — | — | WO | claimed |
| US-12285489-B2 | Bone targeted antimicrobial oxazolidinone related compounds, formulations thereof, and uses thereof | EBETINO FRANK HALLOCK (US) | 2025-04-29 | — | — | US | claimed |
| US-20250129084-A1 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-04-24 | — | — | US | claimed |
| WO-2025080590-A1 | CO-CRYSTALLIZATION OF ACTIVES WITH SACCHARIDE-BASED MOLECULAR FRAMEWORKS | SCIENTIFIC HORIZONS CONSULTING LLC (US) | 2025-04-17 | — | — | WO | claimed |
| US-20220170104-A1 | BACTERIAL ETIOLOGY OF COLORECTAL CANCER | DANA-FARBER CANCER INSTITUTE, INC. | 2022-06-02 | — | — | US | claimed |
| WO-2022114728-A2 | COMPOSITION COMPRISING SHMT INHIBITOR OR MTHFR INHIBITOR FOR TREATING BACTERIAL INFECTION | 성균관대학교산학협력단 | 2022-06-02 | — | — | WO | claimed |
| EP-3965808-A1 | USE OF PARASITES AND EXTRACELLULAR VESICLES OBTAINED FROM PARASITES IN CANCER TREATMENT | Yeditepe Universitesi (TR) | 2022-03-16 | — | — | EP | claimed |
| US-11248259-B2 | Method of identifying a subject having a bacterial infection | IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE (GB) | 2022-02-15 | — | — | US | claimed |
| EP-2635307-B1 | PHARMACEUTICAL COMPOSITIONS | MELINTA SUBSIDIARY CORP (US) | 2020-07-29 | — | — | EP | claimed |
| US-9409896-B2 | Sustained release pharmaceutical compositions comprising an antibacterial agent | MELINTA THERAPEUTICS, INC. (US) | 2016-08-09 | — | — | US | claimed |
| US-9126991-B2 | Radezolid salts and polymorphic forms thereof | LI HUI-YIN (US) | 2015-09-08 | — | — | US | claimed |
| US-20140100254-A1 | Radezolid salts and polymorphic forms thereof | LI HUI-YIN (US) | 2014-04-10 | — | — | US | claimed |
| EP-2635307-A2 | PHARMACEUTICAL COMPOSITIONS | Rib-X Pharmaceuticals, Inc. (US) | 2013-09-11 | — | — | EP | claimed |
| WO-2012061360-A2 | PHARMACEUTICAL COMPOSITIONS | RIB-X PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027140-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | IL1B, IL5, SERPINB1 | MAOA 416/4885CALML3 1297/4885MAOB 46/4885 |
| US-20250129084-A1 | Compounds | CFTR, TBCA, TBCD | MAOA 2138/4885CALML3 2453/4885MAOB 1545/4885 |
| US-20140100254-A1 | Radezolid salts and polymorphic forms thereof | RPL27A, GRHPR, RAD52 | MAOA 3452/4885CALML3 2920/4885MAOB 2745/4885 |
| US-20260048047-A1 | SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE | FNTB, PDE7A, TBL3 | MAOA 1993/4885CALML3 1019/4885MAOB 1339/4885 |
| US-12285489-B2 | Bone targeted antimicrobial oxazolidinone related compounds, formulations thereof, and uses thereof | SOST, BPGM, PTMS | MAOA 3576/4885CALML3 4370/4885MAOB 2694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.